13 citations
,
March 2002 in “Pediatric Dermatology” This article discusses temporal triangular alopecia, emphasizing the need for increased awareness to prevent misdiagnosis and ineffective treatment, but reports no new clinical results.
7 citations
,
March 2004 in “Journal of the American Academy of Dermatology” Tiger tail banding and hair abnormalities are reliable indicators for diagnosing trichothiodystrophy.
August 2022 in “Dermatology Online Journal” Oral and topical tofacitinib can effectively treat severe hair loss with minimal side effects.
November 2025 in “SKIN The Journal of Cutaneous Medicine” In this phase 3 trial, baricitinib showed effectiveness and safety in both adolescents and adults with severe alopecia areata, with adolescents achieving higher response rates despite more severe baseline conditions, suggesting the advantages of early treatment.
May 2025 in “JEADV Clinical Practice” This case study reports significant improvements in joint pain and hair regrowth in a 31-year-old female with alopecia universalis, psoriasis vulgaris, and psoriatic arthritis using a combination of tofacitinib and methotrexate after other treatments failed.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” This study identified intramembrane proteolysis as a key feature of Astrotactin2 maturation, providing insights into its role in planar cell polarity hair patterning.
1 citations
,
July 2019 in “Medicina Clínica (English Edition)” Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
January 2020 in “JAAD case reports” Systemic mastocytosis may cause a type of hair loss called cicatricial alopecia.
1 citations
,
August 2022 in “Journal of Dermatology and Dermatologic Surgery” In this case report, tofacitinib was initiated in a 20-year-old female with alopecia universalis resistant to topical treatments, but resulted in a mild peripheral neuropathy side effect.
July 2023 in “Skin Research and Technology” This study reports that combining baricitinib with low-dose cyclosporine and steroids resulted in effective and safe treatment for a case of alopecia totalis, maintaining hair regrowth without adverse effects.
January 2018 in “Journal of the American Academy of Dermatology” This letter discusses a previous study on tofacitinib for alopecia areata, questioning its statistical analysis and suggesting that steroids may have influenced results, but it reports no new clinical findings.
January 2024 in “Dermatologic therapy” In this study, pediatric patients with alopecia areata treated with systemic tofacitinib showed significant improvement at 12 months, but the small sample size and retrospective design limit conclusions about its effectiveness.
1 citations
,
April 2018 in “Journal of Investigative Dermatology” This open-label study found that oral tofacitinib led to significant hair regrowth in patients with moderate-to-severe alopecia areata, supported by changes in gene expression and T cell dynamics.
December 2020 in “TURKDERM” This case report describes a 3-year-old boy diagnosed with temporal triangular alopecia, emphasizing the importance of clinical and dermoscopic examination for correct diagnosis due to the condition's rarity and risk of misdiagnosis.
54 citations
,
September 2019 in “Journal of the European Academy of Dermatology and Venereology” This study found that tofacitinib shows reasonable effectiveness for treating alopecia areata with mild adverse effects, although more large-scale randomized trials are needed to fully assess its safety and efficacy.
8 citations
,
June 2022 in “Frontiers in Medicine” This study found that tofacitinib is an effective and more tolerable treatment than systemic corticosteroids for moderate-to-severe alopecia areata, and its combination with corticosteroids may offer improved efficacy.
In this study, the combined treatment of ursolic acid and resveratrol was evaluated for its inhibitory effects on skin tumor promotion in female FVB mice. The combination was applied topically before TPA treatment and was found to significantly inhibit TPA-induced epidermal hyperproliferation, signaling pathways, and skin inflammation more effectively than either compound alone. Key signaling pathways affected included EGFR, STAT3, and NF-κB, among others. The combination also increased tumor suppressor levels and reduced proinflammatory cytokine expression. Overall, the combined treatment resulted in a greater reduction in tumor multiplicity and size, highlighting its potential as a more effective strategy for preventing skin tumor promotion compared to individual treatments.
March 2025 in “Journal of Investigative Dermatology” 
October 2025 in “Indian Journal of Dermatology” This study examined the dermoscopic features of five patients with tuberous sclerosis and found that dermoscopy can differentiate characteristic cutaneous features from similar conditions, potentially aiding in earlier diagnosis when other symptoms are subtle or absent.
April 2012 in “Neuropediatrics” This article reviews the genetic and phenotypic characteristics of Trichothiodystrophy and discusses the associated DNA repair defects, but does not report new clinical findings.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” In this study, tofacitinib was reported to improve scalp hair regrowth in patients with severe alopecia areata, alopecia totalis, and alopecia universalis, showing a higher response in alopecia areata.
January 2025 in “Journal of Crohn s and Colitis” In this study, tofacitinib showed promising efficacy and safety for biologic-naïve elderly patients with moderate-to-severe ulcerative colitis, achieving steroid-free remission and clinical response over 52 weeks.
September 2025 in “Stem Cell Research & Therapy” This study found that TAZ promotes adipogenesis in goat adipose-derived mesenchymal stem cells by enhancing PI3K/AKT pathway activity, with overexpression boosting adipocyte formation and knockdown inhibiting it.
April 2026 in “Clinical and Translational Science” In this multi-center, retrospective cohort study, researchers found that tofacitinib significantly reduced SALT scores and improved eyebrow and eyelash regrowth in patients with refractory alopecia areata after 12 weeks, with greater efficacy observed in severe cases and consistent results across pediatric and adult populations.
4 citations
,
January 2001 in “Archives of Biochemistry and Biophysics” This study found that TPA induces apoptosis in pig renal epithelial cells by affecting cell cycle proteins, and activated ras can prevent this process.
In this study, the combined treatment of ursolic acid and resveratrol was evaluated for its effects on skin tumor promotion in female FVB mice. The combination was applied topically before TPA treatment and was found to significantly inhibit TPA-induced epidermal hyperproliferation, signaling pathways, and skin inflammation more effectively than either compound alone. Key signaling pathways affected included EGFR, STAT3, and NF-κB, among others. The combination also increased tumor suppressor levels and reduced proinflammatory cytokine expression. Overall, the combined treatment resulted in a greater reduction in tumor multiplicity and size, highlighting its potential as a more effective strategy for inhibiting skin tumor promotion compared to individual treatments.
13 citations
,
November 2021 in “Pediatric Dermatology” This study found that oral tofacitinib was effective and well tolerated for treating alopecia areata in most pediatric patients, with nearly 73% experiencing hair regrowth.
June 2017 in “Journal of The American Academy of Dermatology” Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.
November 1968 in “Journal of the American Pharmaceutical Association” 
June 2020 in “Journal of Investigative Dermatology” This study observed that insurance coverage for oral tofacitinib in alopecia areata patients was difficult to obtain, with 71% of patients ultimately not receiving approval despite the drug's efficacy as an off-label treatment.